Form 4: Apogee Therapeutics' Chief Medical Officer Sells Shares Under 10b5-1 Trading Plan

Carl Dambkowski, Chief Medical Officer of Apogee Therapeutics, sold 1,590 shares of common stock at $30.48 per share on March 5, 2025, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On March 5, 2025, Carl Dambkowski, the Chief Medical Officer of Apogee Therapeutics, Inc. (APGE), sold 1,590 shares of the company's common stock.
• The sale was executed at a price of $30.48 per share.
• This transaction was conducted under a Rule 10b5-1 trading plan that was adopted on August 21, 2024.
• Following the transaction, Dambkowski still beneficially owns 251,033 shares of Apogee Therapeutics' common stock.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the transaction is a routine sale under a pre-arranged trading plan and doesn't necessarily indicate a negative outlook on the company.

Industry Context

Sales by company insiders are a common occurrence and are often pre-planned through Rule 10b5-1 trading plans to avoid accusations of trading on inside information. The market typically analyzes these sales in the context of the company's performance and future prospects.

Stakeholder Impact

• The sale of shares by a high-ranking officer could potentially create uncertainty among shareholders, although the existence of a 10b5-1 plan mitigates this concern.

Key Dates